Kodiak Sciences

Kodiak Sciences is a clinical-stage biopharmaceutical company specializing in developing new therapies for chronic, highly prevalent retinal diseases. Kodiak Sciences Inc.'s most advanced product candidate is KSI-301, a biologic therapy constructed using the Antibody Biopolymer Conjugate platform, or ABC platform, designed to sustain effective and potent drug levels in ocular tissues.